The therapies listed below appear to have had development paused by their sponsors. The reasons for interrupting development can be multiple, such as lack of efficacy (i.e., Phase 2/3 clinical trial sponsored by the company did not meet its primary endpoint), safety concerns, unfavourable risk-benefit profile, insufficient market potential or regulatory setbacks.
This list includes therapies that were in development from approximately 2023 onwards. If you have any questions or concerns, please feel free to contact alliance@als-mnd.org.